Dr. Jeannine McCune is a distinguished Cancer Pharmacologist renowned for her pioneering work in optimizing anticancer therapies through precision medicine approaches. She currently serves as Professor in Hematologic Malignancies and Translational Sciences at the Beckman Research Institute of City of Hope National Medical Center, where she has established herself as a leading authority in clinical pharmacology. Holding both a PharmD and PhD, Dr. McCune brings a unique dual perspective that bridges pharmaceutical science with clinical oncology to improve therapeutic outcomes for cancer patients. Her academic journey has been marked by strategic appointments at premier research institutions, culminating in her current leadership position where she directs critical studies on drug efficacy and safety profiles. Dr. McCune's professional trajectory reflects her unwavering commitment to advancing personalized cancer treatment through rigorous scientific investigation and translational research.
Dr. McCune's groundbreaking research has centered on quantifying drug exposure of anticancer agents and immunosuppressants to develop individualized treatment protocols that maximize therapeutic benefits while minimizing adverse effects. She has secured multiple major National Institutes of Health grants to investigate tailored medicine approaches for both pediatric and adult cancer patients, demonstrating her work's significant impact on the field. Her methodological innovations in therapeutic drug monitoring have provided clinicians with essential tools to optimize dosing strategies based on individual patient characteristics and genetic profiles. With over 130 scholarly publications, Dr. McCune has established herself as a prolific contributor to cancer pharmacology, with her work frequently cited for its methodological rigor and clinical relevance. Her research on sirolimus and other immunosuppressive agents has particular importance for patients undergoing hematopoietic cell transplantation, addressing critical challenges in post-transplant care.
Beyond her individual research contributions, Dr. McCune has played a pivotal role in shaping the broader landscape of cancer pharmacology through her active participation in national research consortia and collaborative initiatives. Her expertise is regularly sought for scientific advisory panels where she helps set research priorities and methodological standards for clinical pharmacology studies. Dr. McCune has mentored numerous junior researchers and clinicians, fostering the next generation of scientists dedicated to advancing personalized cancer treatment approaches. Her current research focuses on overcoming barriers to equitable implementation of pharmacogenomic testing in diverse patient populations, addressing critical disparities in precision medicine access. As she continues her NIH-funded investigations, Dr. McCune remains committed to translating pharmacological insights into tangible clinical improvements that benefit cancer patients across demographic and socioeconomic spectrums.
